Hugo Vanerman

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Viseon, Inc. engages in providing medical devices. It offers cannulae and sheaths for minimally invasive surgical access to the spine, imaging systems for spinal surgery, soft tissue resection devices, and fluid aspiration devices for use in spinal surgery. The company was founded in 1993 and is headquartered in Irvine, CA.

Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.

Israel Aerospace Industries Ltd. engages in the development, sale, and maintenance of commercial and military aircrafts, missiles, and military electronic products. It operates through the following segments: Aviation, Military Aircraft, Missiles and Space Systems, and Elta Systems Ltd. The Aviation segment engages in the maintenance, renovation, and improvement of aircraft and aircraft engines, and conversion of passenger aircraft into cargo and refueling aircraft, and in the development and manufacture of aviation assemblies for military and commercial aircraft. The Military Aircraft segment engages in the development, manufacture, and sale of unmanned aircraft. The Missiles and Space Systems segment engages in the development, manufacture, and sale of attack and defense missile systems, satellites, and space assemblies. The Elta Systems Ltd segment engages in the military electronics field. The company was founded in 1953 and is headquartered in Lod, Israel.

NeoSync, Inc. is a clinical-stage firm. It develops non-invasive neuromodulation products to treat major depressive disorder and other diseases of the central nervous system. The firm's technology, NeoSync-EEG Synchronized TMS, is personalized to a patient’s individual alpha frequency. The company was founded by Bill Phillips and is headquartered in South Boston, MA.

Vascular Dynamics, Inc. provides blood pressure modulation devices. It develops and commercializes a passive, catheter-delivered implant for the treatment of hypertension. The company was founded in 2008 and is headquartered in Mountain View, CA.

Element Science, Inc. operates as a medical device and digital health company. It develops a wearable platform solution with proprietary technology in wearable patches, electrical design, machine learning algorithms and digital solutions. The company was founded by Uday N. Kumar in 2011 and is headquartered in San Francisco, CA.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Synergia Capital Partners BV is an independent private equity investment firm based in Veenendaal, the Netherlands. Founded in 1999, they specialize in the mid-size market of Dutch firms. Synergia operates through a range of transactions such as MBOs/MBIs, BIMBOs, public-to-private, growth finance and secondary offerings.

MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.

EarlySense Ltd. provides patient monitoring systems. It offers continuous patient monitoring for heart rate, respiratory rate and motion, to potentially allow the clinical team to manage early detection of patient deterioration, fall prevention and pressure ulcers prevention. The firm develops system specifically for medical surgical, general care patients who are usually monitored by nurses once every four to six hours. The company was founded by Avner Halperin, Daniel H. Lange, Guy Shinar and Yossi Gross in 2004 and is headquartered in Ramat Gan, Israel.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

DuoCure Ltd. develops intraluminal minimally invasive implantable devices for the treatment of obesity. The company was founded by Elad Magal, Yossi Gross and Yael Karasik in 2005 and is headquartered in Tel Aviv, Israel.

BetaStim Ltd. develops medical devices. The firm's implantable pulse generator is used to treat type II diabetes by applying electrical stimulation and monitoring gastrointestinal electrical activity. The company was founded by Yossi Gross and Jacob Ben Arie in 2006 and is headquartered in Caesarea, Israel.

Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel.

Valtech Cardio Ltd. develops devices for mitral valve repair and replacement. It specializes in the development of devices for mitral and tricuspid valve repair and replacement. The firm also offers full in-house development, manufacturing and clinical research capabilities, and patent applications. The company was founded by Amir Gross and Yossi Gross in March 2005 and is headquartered in Or Yehuda, Israel.

Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

UniversitätsSpital Zürich is a renowned university hospital that specializes in university medicine, nursing, research, and teaching. UniversitätsSpital Zürich is based in Zurich, Switzerland. With over 42,000 inpatients and 600,000 outpatient consultations annually, the hospital has gained the trust of many patients. The hospital has approximately 8,500 employees and collaborates with over 40 clinics and institutes, providing patients with the expertise of its specialists and modern therapies. Gregor Zünd has been the CEO of the Swiss company since 1989.

Nano Retina Ltd. develops artificial retina designed to restore sight. It also develops an implantable bionic chip, designed to return sight to those blinded by retinal degenerative diseases. The company was founded by Yossi Gross and James R. Von Her, II in 2009 and is headquartered in Herzliya, Israel.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Magenta Medical Ltd. develops medical devices for the treatment of acute and congestive heart failure. It offers a temporary venous catheter-based therapy for hospital-admitted patients. The firm?s novel therapeutic principle is aimed at addressing renal venous congestion and its deleterious effects on renal and cardiac function that is a pathophysiological core element of acute heart failure. The company was founded by Ehud Schwammenthal and Yosi Tuval in October 2012 and is headquartered in Kadima, Israel.

Invus Financial Advisors LLC (Invus Financial Advisors) is a private equity firm founded in 2006 by Leslie L. Lake and Sacha Lainovic. The firm is headquartered in New York.

ChroniSense Medical Ltd. provides healthcare services. It develops wearable medical-grade devices that monitor vital signs and other health factors. The firm''s sensors measure medical data from blood oxygen and ECG to blood pressure, cardiac output and vascular resistance, and communicate that data to caregivers in real time. The company was founded by Danny B. Lange and Yossi Gross in 2015 and is headquartered in Yokneam, Israel.

Part of Venus Medtech (Hangzhou), Inc., Cardiovalve Ltd. is an Israeli medical device company that specializes in developing the Cardiovalve transcatheter system. The company is based in Or Yehuda, Israel. The system is designed to replace regurgitating mitral and tricuspid valves using a transfemoral-transseptal approach. The CEO of the company is Amir Gross. Cardiovalve was acquired by Athena Medtech Holding Ltd. on January 25, 2022 for $83.98 million.

Mission Lane Holdings, Inc. operates as an investment holding company. The company is headquartered in San Francisco, CA.

Wave Financial Group LLC provides financial services. It offers early-stage investment, asset, treasury management and strategy consulting services. The company was founded by David Siemer and is headquartered in Los Angeles, CA.

Cooperative Energy Futures generates solar electric power. The company is headquartered in Minneapolis, MN.

Part of Wave Digital Assets LLC, Wave NFT Fund, LP operates as an investment fund. The company is based in Los Angeles, CA.

HVR Cardio Oy is a Finnish cardiovascular device company that is developing breakthrough solutions for mitral valve repair based on its proprietary helix technology. The company is based in Espoo, Finland. The company's lead products, CathHELIX® and MAR®, are transcatheter and surgical mitral valve repair devices that are designed to be faster, easier to use, and less invasive without compromising clinical efficacy. The company was founded by Olli Urho Tapani Keränen, and Tom Fleming has been the CEO of the company since 2022.